Kamil Ali-Jackson
CIK: 0001654337
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (6 total)
- Jun 22, 2026RIGL
RIGEL PHARMACEUTICALS INC
Sale(S)Direct2.5K shares at avg. $35.00$88K - May 26, 2026RIGL
RIGEL PHARMACEUTICALS INC
Sale(S)Direct2.5K shares at avg. $29.17$73K - May 15, 2026RIGL
RIGEL PHARMACEUTICALS INC
Award(A)Direct5.8K shares- - Jan 12, 2026PDSB
PDS Biotechnology Corp
Award(A)DirectEmployee Stock Option (Right to Buy)
54.9K shares- - Jun 11, 2025PDSB
PDS Biotechnology Corp
Award(A)DirectEmployee Stock Option (Right to Buy)
22.7K shares- - May 23, 2025RIGL
RIGEL PHARMACEUTICALS INC
Award(A)Direct2.5K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 22, 2026 |  RIGL RIGEL PHARMACEUTICALS INC | Sale(S) | 2,500 | $35.00 | $87,500 | Direct |
| May 26, 2026 | RIGL RIGEL PHARMACEUTICALS INC | Sale(S) | 2,500 | $29.17 | $72,925 | Direct |
| May 15, 2026 | RIGL RIGEL PHARMACEUTICALS INC | Award(A) | 5,750 | - | $0 | Direct |
| Jan 12, 2026 |  PDSB PDS Biotechnology Corp | Award(A) Employee Stock Option (Right to Buy) | 54,876 | - | - | Direct |
| Jun 11, 2025 | PDSB PDS Biotechnology Corp | Award(A) Employee Stock Option (Right to Buy) | 22,700 | - | - | Direct |
| May 23, 2025 | RIGL RIGEL PHARMACEUTICALS INC | Award(A) | 2,500 | - | - | Direct |
1-6 of 6 transactions
About Ali-Jackson Kamil
Ali-Jackson Kamil (SEC CIK 0001654337) files insider reports with the SEC as Director of RIGEL PHARMACEUTICALS INC (RIGL) and Director of PDS Biotechnology Corp (PDSB).
Signal8 holds 6 ownership filings by Ali-Jackson Kamil, all Form 4s, filed between May 28, 2025 and Jun 24, 2026. Those filings report 6 transactions, from May 23, 2025 to Jun 22, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Ali-Jackson Kamil's filings is in SOUTH SAN FRANCISCO, CA.
Recent filings by Ali-Jackson Kamil
- Jun 22, 2026: Open-market sale of RIGL shares (Form 4, code S).
- May 26, 2026: Open-market sale of RIGL shares (Form 4, code S).
- May 15, 2026: Grant or award of RIGL shares (Form 4, code A).
- Jan 12, 2026: Grant or award of PDSB derivative securities (Form 4, code A).
- Jun 11, 2025: Grant or award of PDSB derivative securities (Form 4, code A).
Other insiders filing for RIGEL PHARMACEUTICALS INC (RIGL)
- Schorno Dean L, EVP & Chief Financial Officer
- Santos David A, EVP, Chief Commercial Officer
- RODRIGUEZ RAUL R, CEO, President
- Furey Raymond J., EVP, GC, CCO & Corp Sec
- HANNAH ALISON L., EVP, Chief Medical Officer
- Rojkjaer Lisa, EVP, Chief Medical Officer